The effect of a low dose of clenbuterol on rat soleus muscle submitted to joint immobilization.
The aim of the present study was to evaluate the effect of joint immobilization on morphometric parameters and glycogen content of soleus muscle treated with clenbuterol. Male Wistar (3-4 months old) rats were divided into 4 groups (N = 6 for each group): control, clenbuterol, immobilized, and immobilized treated with clenbuterol. Immobilization was performed with acrylic resin orthoses and 10 microg/kg body weight clenbuterol was administered subcutaneously for 7 days. The following parameters were measured the next day on soleus muscle: weight, glycogen content, cross-sectional area, and connective tissue content. The clenbuterol group showed an increase in glycogen (81.6%, 0.38 +/- 0.09 vs 0.69 +/- 0.06 mg/100 g; P < 0.05) without alteration in weight, cross-sectional area or connective tissue compared with the control group. The immobilized group showed a reduction in muscle weight (34.2%, 123.5 +/- 5.3 vs 81.3 +/- 4.6 mg; P < 0.05), glycogen content (31.6%, 0.38 +/- 0.09 vs 0.26 +/- 0.05 mg/100 mg; P < 0.05) and cross-sectional area (44.1%, 2574.9 +/- 560.2 vs 1438.1 +/- 352.2 microm(2); P < 0.05) and an increase in connective tissue (216.5%, 8.82 +/- 3.55 vs 27.92 +/- 5.36%; P < 0.05). However, the immobilized + clenbuterol group showed an increase in weight (15.9%; 81.3 +/- 4.6 vs 94.2 +/- 4.3 mg; P < 0.05), glycogen content (92.3%, 0.26 +/- 0.05 vs 0.50 +/- 0.17 mg/100 mg; P < 0.05), and cross-sectional area (19.9%, 1438.1 +/- 352.2 vs 1724.8 +/- 365.5 microm(2); P < 0.05) and a reduction in connective tissue (52.2%, 27.92 +/- 5.36 vs 13.34 +/- 6.86%; P < 0.05). Statistical analysis was performed using Kolmogorov-Smirnov and homoscedasticity tests. For the muscle weight and muscle glycogen content, two-way ANOVA and the Tukey test were used. For the cross-sectional area and connective tissue content, Kruskal-Wallis and Tukey tests were used. This study emphasizes the importance of anabolic pharmacological protection during immobilization to minimize skeletal muscle alterations resulting from disuse.
Cancelliero
K M
KM
Departamento de Fisioterapia, Universidade Federal de São Carlos, São Carlos, SP, Brasil.
Durigan
J L Q
JL
Vieira
R P
RP
Silva
C A
CA
Polacow
M L O
ML
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002976:Clenbuterol / Q000008:administration & dosage / Q000494:pharmacology*; D003238:Connective Tissue / Q000187:drug effects*; D006003:Glycogen / Q000032:analysis*; D007103:Immobilization; D008297:Male; D018485:Muscle Fibers, Skeletal / Q000187:drug effects; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D009133:Muscular Atrophy / Q000517:prevention & control; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D000318:Adrenergic beta-Agonists; D006003:Glycogen; D002976:Clenbuterol